Suppr超能文献

弥漫性组织细胞淋巴瘤。积极进行再分期的必要性。

Diffuse histiocytic lymphoma. The need for aggressive restaging.

作者信息

Weinerman B H, Levitt M, Babick T

出版信息

JAMA. 1977 May 30;237(22):2403-4. doi: 10.1001/jama.237.22.2403.

Abstract

Fifteen patients with stage III and IV diffuse histiocytic lymphoma were treated with combination chemotherapy: cyclophosphamide, vincristine sulfate, prednisone, and procarbazine hydrochloride (COPP). Eight achieved a complete clinical remission. Of these, five relapsed, but remission was reinduced in three of these. Median survival of partial responders was 52 weeks compared to more than 129 weeks for complete responders. Complete clinical remission in diffuse histiocytic lymphomas did not presage a long disease-free interval as has been reported in biopsy proved remission series. Biopsy and staging by pathologic examination appear necessary to document remission in this disease.

摘要

15例Ⅲ期和Ⅳ期弥漫性组织细胞淋巴瘤患者接受了联合化疗:环磷酰胺、硫酸长春新碱、泼尼松和盐酸丙卡巴肼(COPP方案)。8例患者实现了完全临床缓解。其中5例复发,但其中3例再次诱导缓解。部分缓解者的中位生存期为52周,而完全缓解者超过129周。弥漫性组织细胞淋巴瘤的完全临床缓解并不预示着如活检证实的缓解系列报道中那样有较长的无病间期。病理检查进行活检和分期似乎对于记录该疾病的缓解情况是必要的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验